menu

Investors & Media

Press Releases

Press Releases

Keyword Search

Apr 23, 2024
Ionis to hold first quarter 2024 financial results webcast
Apr 07, 2024
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Apr 01, 2024
Ionis to present at upcoming investor conferences
Mar 28, 2024
Ionis to hold olezarsen Phase 3 data webcast
Mar 25, 2024
Positive olezarsen Phase 3 data in familial chylomicronemia syndrome to be presented at 2024 American College of Cardiology (ACC) annual meeting
Mar 13, 2024
Ionis announces positive results from Phase 2 study of ION224, an investigational medicine demonstrating clinical efficacy in the treatment of NASH/MASH
Feb 29, 2024
Ionis announces new chief global product strategy officer to lead next phase of commercial growth
Feb 28, 2024
Ionis to present at upcoming investor conferences
Feb 21, 2024
Ionis reports fourth quarter and full year 2023 financial results
Feb 15, 2024
Olezarsen receives Orphan Drug designation from U.S. FDA for familial chylomicronemia syndrome
Feb 08, 2024
Eplontersen granted U.S. FDA Fast Track designation for patients with transthyretin-mediated amyloid cardiomyopathy
Feb 07, 2024
Ionis to hold fourth quarter and full year 2023 financial results webcast
Jan 22, 2024
Ionis announces positive topline results from Phase 3 OASIS-HAE study of investigational donidalorsen in patients with hereditary angioedema
Jan 08, 2024
Ionis poised for continued momentum in 2024 with product launches and key advances in robust pipeline of investigational medicines for serious diseases
Load More »